AR110197A1 - Formas sólidas de un inhibidor de bet - Google Patents

Formas sólidas de un inhibidor de bet

Info

Publication number
AR110197A1
AR110197A1 ARP170103237A ARP170103237A AR110197A1 AR 110197 A1 AR110197 A1 AR 110197A1 AR P170103237 A ARP170103237 A AR P170103237A AR P170103237 A ARP170103237 A AR P170103237A AR 110197 A1 AR110197 A1 AR 110197A1
Authority
AR
Argentina
Prior art keywords
solid forms
bet inhibitor
compound
forms
formula
Prior art date
Application number
ARP170103237A
Other languages
English (en)
Inventor
Jinyu Shen
Pavel R Badalov
Ekaterina Albert
Olga Viktorovna Lapina
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR110197A1 publication Critical patent/AR110197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se prepararon formas de (2-ciclopropil-6-(3,5-dimetilisoxazol-4-il)-1H-benzo[d]imidazol-4-il)di(piridin-2-il)metanol (Compuesto I) de fórmula (1) y se caracterizaron en estado sólido. También se proveen procesos de preparación y métodos de uso de las formas del Compuesto I. Reivindicación 1: Un complejo de fosfato del Compuesto I de fórmula (1) caracterizado porgue posee forma cristalina.
ARP170103237A 2016-11-22 2017-11-22 Formas sólidas de un inhibidor de bet AR110197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662425193P 2016-11-22 2016-11-22

Publications (1)

Publication Number Publication Date
AR110197A1 true AR110197A1 (es) 2019-03-06

Family

ID=60543694

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103237A AR110197A1 (es) 2016-11-22 2017-11-22 Formas sólidas de un inhibidor de bet

Country Status (4)

Country Link
US (1) US20180141939A1 (es)
AR (1) AR110197A1 (es)
TW (1) TW201823238A (es)
WO (1) WO2018097977A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
TWI841598B (zh) * 2018-09-13 2024-05-11 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療雌激素受體陽性乳癌之組合療法
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
US20220354874A1 (en) * 2019-06-21 2022-11-10 Pattern Computer, Inc. Therapeutic compositions and methods for treating cancers
WO2021062238A1 (en) * 2019-09-27 2021-04-01 The University Of Chicago Methods and compositions for treating sickle cell disease and thalassemia
CN111317743B (zh) * 2020-03-13 2022-11-29 中国人民解放军第四军医大学 一种基于Kif11基因的重组腺相关病毒抑制病理性疼痛的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
MX2012009088A (es) 2010-02-04 2012-12-05 Gilead Biologics Inc Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
PL2608809T3 (pl) 2010-08-27 2019-10-31 Gilead Biologics Inc Przeciwciała dla metaloproteinazy 9 macierzy
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
TW201427995A (zh) 2012-09-24 2014-07-16 Gilead Sciences Inc 抗ｄｄｒ１抗體
BR112015014592A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método para o tratamento de um humano
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
BR112015031475A2 (pt) 2013-06-14 2017-07-25 Gilead Sciences Inc composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Also Published As

Publication number Publication date
US20180141939A1 (en) 2018-05-24
TW201823238A (zh) 2018-07-01
WO2018097977A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
AR110197A1 (es) Formas sólidas de un inhibidor de bet
CO2017006099A2 (es) Formas sólidas de un inhibidor ask1
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
TWD181303S (zh) 晶圓載具
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
TWD181302S (zh) 晶圓載具
CL2018002101A1 (es) Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización
CL2018002094A1 (es) Un proceso para preparar compuesto de pirrolo[3,2–d]pirimidina y su intermediario
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
PH12019501514A1 (en) Integrin antagonists
CL2019000568A1 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
EP3888671A3 (en) Protein formulations
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
AR109893A1 (es) Formas cristalinas de darunavir
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure